

<b>Candidate clinical features for initial model input</b>	
Demographics	
	Age at diagnosis
	Sex
	Race
	Ethnicity
	Time to treatment initiation
Complete blood count with differential	
	White blood cell count
	Absolute lymphocyte count
	Absolute neutrophil count
	Hemoglobin
	Mean corpuscular volume
	Mean corpuscular hemoglobin concentration
	Red cell distribution width
	Platelets
Chemistries	
	Sodium
	Potassium
	Chloride
	Total calcium
	Magnesium
	Phosphate
Cardiovascular function	
	NT-proBNP
	HSTnT
	NYHA class
	LVEF
	Global longitudinal strain
	Interventricular septal thickness
	Histopathologic examination of biopsied tissue
Renal function	
	Serum creatinine
	eGFR (2021 CKD-EPI)
	Urine protein-creatinine ratio
	24h urine protein
	Histopathologic examination of biopsied tissue
Hepatic function	
	Albumin
	Aspartate aminotransferase
	Alanine aminotransferase
	Total bilirubin
	Alkaline phosphatase
Coagulation	

	INR
	aPTT
	Fibrinogen
Plasma cell-specific assays	
	Involved light chain subtype
	IgA
	IgG
	IgM
	M-protein
	Kappa FLC
	Lambda FLC
	Beta-2 microglobulin
	Lactate dehydrogenase
	Bone marrow plasma cell percentage
Other markers	
	Ferritin
	Triglycerides
Treatment	
	Daratumumab-containing regimen administered
	Time on therapy, overall
	Dose delays
	Dose modifications
	Drug discontinuations
	Adverse events- infections
	Adverse events- other
	Hospitalization- cardiac (+ timing)
	Hospitalization- other (+ timing)
	Diuretics- dose, number
	Diuretics- timing of prescription
	Autologous stem cell transplant
	ASCT- melphalan dose
	ASCT- time to ASCT if performed
Hematologic course	
	Graded response at 1 month and every 3 months thereafter to 36 months
	Best response
	Time to first response
	Time to best response